Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 517-522

  Kimura, Yuki ^a   Hyogo, Hideyuki ^a   Ishitobi, Tomokazu ^a   Nabeshima, Yoshitaka ^a   Arihiro, Koji ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Fibrosis; Insulin; Non alcoholic fatty liver disease; Oral glucose tolerance test

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 79951599555     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06567.x     Document Type: Article

References (41)

1. Teli MR, James OF, Burt AD etal. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
2. Dam-Larsen S, Franzmann M, Andersen IB etal. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
3. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
4. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999; 353: 1634-6.
5. Chitturi S, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
6. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
7. Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J. Gastroenterol. Hepatol. 2003; 18: 1115-7.
8. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
9. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 2008; 118: 829-38.
10. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 18: 1221-31.
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
12. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr. Rev. 2007; 65: S57-63.
13. Neuschwander-Tetri BA, Clark JM, Bass NM etal. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-24.
14. Larter CZ, Chitturi S, Heydet D etal. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J. Gastroenterol. Hepatol. 2010; 25: 672-90.
15. Fracanzani AL, Valenti L, Bugianesi E etal. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.
16. Fafiq N. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 2009; 7: 234-8.
17. Hossain N, Afendy A, Stepanova M etal. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009; 7: 1224-9.
18. Sonsuz A, Basaranoglu M, Bilir M etal. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2002; 97: 495.
19. Whalan DJ. The ethics and morality of clinical trials in man. Med. J. Aust. 1975; 19: 491-4.
20. Iwamoto K, Kanno K, Hyogo H etal. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J. Gastroenterol. 2008; 43: 298-304.
21. Hyogo H, Tazuma S, Arihiro K etal. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
22. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5-S20.
23. Matthews DR, Hosker JP, Rudenski AS etal. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
24. Brunt EM, Janney CG, Di Bisceglie AM etal. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
25. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
26. Angulo P, Keach JC, Batts KP etal. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 917-23.
27. Sargin M, Uygur-Bayramiçli O, Sargin H etal. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J. Clin. Gastroenterol. 2003; 37: 399-402.
28. Wong VW, Hui AY, Tsang SW etal. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 1215-22.
29. Su CC, Wang K, Hsia TL etal. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J. Clin. Gastroenterol. 2006; 40: 551-4.
30. Wong VW, Hui AY, Tsang SW etal. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 1154-61.
31. Yun JW, Cho YK, Park JH etal. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 2009; 29: 525-9.
32. Nakagami T, Qiao Q, Carstensen B etal. Age, body mass index and type 2 diabetes - associations modified by ethnicity. Diabetologia 2003; 46: 1063-70.
33. Sone H, Yoshimura Y, Ito H etal. Energy intake and obesity in Japanese patients with type 2 diabetes. Lancet 2004; 363: 248-9.
34. Sone H, Yoshimura Y, Tanaka S etal. Cross-sectional association between BMI, glycemic control and energy intake in Japanese patients with type 2 diabetes. Analysis from the Japan Diabetes Complications Study. Diabetes Res. Clin. Pract. 2007; 77 (Suppl. 1): S23-9.
35. Ong JP, Elariny H, Collantes R etal. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 2005; 15: 310-5.
36. Argo CK, Northup PG, Al-Osaimi AM etal. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371-9.
37. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495-500.
38. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
39. Ascha MS, Hanouneh IA, Lopez R etal. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
40. Paradis V, Perlemuter G, Bonvoust F etal. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
41. Paradis V, Dargere D, Bonvoust F etal. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab. Invest. 2002; 82: 767-4.